ALAMEDA, Calif. -- Peninsula Pharmaceuticals, Inc., a privately-held biopharmaceutical company, announces that patient enrollment has begun in a phase III trial of its lead product, doripenem (also known as S-4661), a broad-spectrum carbapenem antibiotic.
The multi-center, double-blind, randomized, phase III trial will evaluate the safety and efficacy of intravenous doripenem in patients with complicated lower urinary tract infections or pyelonephritis. Approximately 450 patients will be enrolled in more than 50 centers in the United States, Europe and South America. The primary endpoint of the study is microbiological response in the microbiologically evaluable population at the test of cure visit, which occurs five to nine days after the completion of therapy.
"We are pleased to be enrolling patients in our first phase III trial soon after completion of our phase II program with doripenem," said Matthew A. Wikler, MD, FIDSA, chief medical officer and executive vice president at Peninsula. "The increasing incidence of resistance of gram-negative bacteria to numerous antibiotics, including fluoroquinolones, requires new drugs to treat hospital-based infections. Doripenem may prove to be an important therapy for infections caused by such resistant bacteria." Shionogi & Co., Ltd., the inventor of doripenem, has filed a New Drug Application for doripenem in Japan with the Japanese Ministry of Health, Labor, and Welfare.
Doripenem is a new member of the carbapenem class of antibacterials. Discovered by Shionogi & Co. Ltd., doripenem has demonstrated in vitro activity against many Gram-positive and Gram-negative bacteria, including penicillin-resistant Streptococcus pneumoniae, extended spectrum beta-lactamase-producing strains (bacteria that produce enzymes which reduce the activity of beta-lactam antibiotics), Pseudomonas aeruginosa and Klebsiella pneumoniae. Peninsula believes that current in vitro and in vivo data support its clinical development as a therapeutic agent for a number of serious bacterial infections.
Source: Peninsula Pharmaceuticals, Inc.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
Broadening the Path: Diverse Educational Routes Into Infection Prevention Careers
July 4th 2025Once dominated by nurses, infection prevention now welcomes professionals from public health, lab science, and respiratory therapy—each bringing unique expertise that strengthens patient safety and IPC programs.
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.